After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

and the author of two books about Israel. He also works with a pro-democracy NGO in Yerevan. Follow him at danperry.substack.com Gilead Sher is a former chief of staff of Israeli prime minister ...

Gilead to report Q4 earnings on Feb. 11, with analysts expecting $1.70 EPS and $7.14B in revenue. Gilead's deal with LEO Pharma includes a $250M upfront payment and up to $1.7B in milestones ...